Abstract Anti-angiogenic therapy is a promising therapeutic strategy for the highly vascular and malignant brain tumor, glioblastoma (GBM), although current clinical trials have failed to demonstrate an extension in overall survival. The small molecule tyrosine kinase inhibitor axitinib that targets vascular endothelial growth factor receptor, potently inhibits angiogenesis and has single-agent clinical activity in non-small cell lung, thyroid, and advanced renal cell cancer. Here we show that axitinib exerts direct cytotoxic activity against a number of patient-derived GBM stem cell (GSCs) and an endothelial cell line, and inhibits endothelial tube formation in vitro. Axitinib treatment of mice bearing hypervascular intracranial tumors generated from human U87 glioma cells, MGG4 GSCs and mouse 005 GSCs significantly extended survival that was associated with decreases in tumor-associated vascularity. We thus show for the first time the antiangiogenic effect and survival prolongation provided by systemic single agent treatment with axitinib in preclinical orthotopic GBM models including clinically relevant GSC models. These results support further investigation of axitinib as an anti-angiogenic agent for GBM.
Introduction
Glioblastoma (GBM) is a malignant brain tumor with a median survival time of 15 months with current multimodality treatment [1] . Despite increased molecular understanding of the tumor and extensive testing of novel investigational therapies, there has been no drastic improvement in the outcome for patients with this brain tumor [2, 3] .
Angiogenesis plays a key role in the progression of glioma [4] , and is mediated by signaling through a number of receptor tyrosine kinases including vascular endothelial growth factor receptor (VEGFR), plateletderived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), epidermal growth factor receptor (EGFR), and Tie-2 receptor, as well as other cell surface receptors such as integrins [5, 6] . Anti-angiogenic therapy is considered a promising treatment option for GBM. Bevacizumab (Avastin Ò ), a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), was approved by the US Food and Drug Administration (FDA) in May 2009 for recurrent GBM [7] . In addition, several targeted drugs such as tyrosinekinase inhibitors (TKIs) have been tested in clinical trials either alone or in combination with other anti-cancer therapies [8, 9] . Clinical studies investigating agents that primarily target the VEGFR pathway have shown some clinical activity for GBM such as modest increases in progression-free survival (PFS) and lowering of corticosteroid use [10] [11] [12] [13] [14] . Unfortunately, recent phase III clinical trials with bevacizumab in newly diagnosed GBM did not show significant improvement in overall survival [15, 16] . While anti-angiogenic therapy remains promising for GBM, it is likely that other anti-angiogenic agents and combinations thereof will be necessary for efficacy improvement.
Axitinib (AG-013736) is an orally active small molecule TKI that selectively inhibits VEGFR-1, -2 and -3 at subnanomolar concentrations, amongst the lowest for any TKI, with additional inhibitory activity against PDGFRb and c-KIT (CD117) [17] [18] [19] . Axitinib inhibits angiogenesis and vascular permeability, which further affects many interactions involved in tumor cell proliferation, tumor progression, and metastasis. In preclinical human xenograft models of breast, colon and lung cancer, melanoma, and neuroblastoma, axitinib exhibited anti-tumor activity that was associated with inhibition of angiogenesis and blood flow [18, 20] . In phase II studies, axitinib showed singleagent activity in a variety of tumor types, including thyroid cancer [21] , advanced renal cell carcinoma [22] and nonsmall cell lung cancer [23] . In a Phase III randomized clinical trial for metastatic renal cell carcinoma, axitinib treatment resulted in longer PFS than sorafenib [24] , and axitinib was approved for therapy-refractory renal cell carcinoma in 2012. However, the efficacy of axitinib for GBM has not yet been explored.
In the past decade cancer stem-like cells have been identified in various solid tumors, including GBM [25, 26] . GBM cancer stem cells (GSCs) are able to self-renew like neural stem cells, efficiently generate orthotopic tumors upon implantation into immunodeficient mice, and can differentiate to cells representative of the bulk of cancer cells. This suggests that GSCs may be responsible for GBM recurrence following conventional therapy, and that successful targeting of GSCs is necessary to cure GBM [27] . We and others previously reported that neurosphere cultures isolated from human GBM specimens enriches for GSCs [28, 29] . Orthotopic tumors derived from GSCs exhibit the phenotypic hallmarks of GBM such as hypervascularity and invasiveness, and maintain genetic aberrations such as EGFR amplification [30] . Thus, GSCsbased xenografts offer a clinically relevant disease model, superior to conventional cell lines, that is ideal for evaluating novel therapeutics for GBM and GSCs [31, 32] . On the other hand, genetically engineered mouse GSCs provide a brain tumor model in syngeneic mice with an intact immune system [33, 34] .
In this study, we first used a number of GSCs and an endothelial cell line to test the effects of axitinib in vitro. We then investigated single agent efficacy of axitinib in three vascular GBM models (human U87 glioma cells and MGG4 GSCs, and mouse 005 GSCs) in vivo.
Materials and methods

Cell lines and reagents
Human U87 glioma cells were obtained from American Type Culture Collection (ATCC, Manassas, VA) and grown in complete Dulbecco's modified Eagle's medium (DMEM) supplemented with 10 % fetal calf serum at 37°C and 5 % CO 2 . Human GSCs MGG4, MGG8, MGG18, BT74 were isolated as previously described [28, 30] , and maintained as spheres in serum-free medium containing 20 ng/mL recombinant human EGF (R&D systems) and 20 ng/mL recombinant human FGF2 (Peprotech). GSCs were passaged by dissociating neurospheres using the Neuro-Cult Chemical Dissociation Kit (StemCell Technologies). Mouse 005 GSCs were provided by Dr. I. Verma (Salk Institute for Biological Studies, La Jolla, CA) [33, 34] . Human umbilical vein endothelial cells (HUVECs) were purchased from Lonza. Human brain microvascular endothelial cells (HBMECs) were obtained from Dr. Ken Arai (MGH). Axitinib (Pfizer Inc) was provided by Pfizer and dissolved in DMSO as a 25 mM stock solution for in vitro studies. The final concentrations added to cells had less than 0.5 % DMSO, which was nontoxic to cells.
Cell viability/cytotoxicity assays Cells were dissociated (GSCs) or trypsinized (HUVECs) and seeded into 96-well plates (5,500 GSCs, or 300 HUVECs/well). The next day, cells were treated with axitinib at varying doses. Five days after incubation, MTS assays (Promega) were performed following manufacturer's instruction. Experiments were done in triplicate and repeated at least two times. Dose-response curves and IC50 values were calculated using Prism (GraphPad Software).
Endothelial tube formation assay
HUVECs or HBMECs were seeded at 4 9 10 4 cells/well on matrigel (Matrigel Matrix, BD Biosciences)-precoated 24-well culture plates and grown in EGM-2 medium (Lonza) with or without axitinib. Twelve (HUVECs) or 32 (HBMECs) hours later, microscopic pictures were captured and tube formation was assessed by counting branching points per field. Three to five fields per well were randomly chosen and each condition was tested in triplicate.
Secondary sphere formation assay
Single cell suspensions of dissociated GSCs were seeded into 96-well plates at 1, 3 or 10 cells/well, and exposed to either control or axitinib at the indicated concentrations. Sixteen days later, the number of wells containing tumor spheres (diameter [60 lm) was recorded.
Flow cytometric analysis
To detect apoptosis induction, GSCs were control or axitinib treated for 48 h and stained with Annexin V and propidium iodide using Annexin V apoptosis detection kit (eBioscience). Analysis was performed with an Accuri flow cytometer (BD Biosciences), and data were analyzed by FlowJo software (Tree Star).
Animal studies
Female athymic nu/nu and C57BL/6 mice aged 6-8 weeks were obtained from NCI Frederick (Frederick, MD). For intracranial tumor establishment, mice were injected stereotactically (2 mm lateral to the bregma at a depth of 3 mm) with 1 9 10 5 U87 (13 mice), 1 9 10 5 MGG4 cells (22 mice) or 2 9 10 4 005 cells (14 mice) in 2 ll DMEM. On day 10 (for U87), day 35 (for MGG4), or day 12 (for 005), mice were randomly divided into two groups, and axitinib (25 mg/kg, dissolved in polyethylene glycol 400 and acidified water) or vehicle solution (polyethylene glycol 400 and acidified water) was injected intraperitoneally daily for 4 weeks (for U87 model), 7 weeks (for MGG4 model, using a 5 days on and 2 days off cycle), or 23 days (for 005 model, 5 days on and 2 days off). Overall health status and body weight were recorded every 2-3 days, and animals were monitored for signs of discomfort or neurologic symptoms. Animals were sacrificed when they showed significant neurologic deficits or lost 15 % of body weight. All in vivo procedures were approved by the Subcommittee on Research Animal Care at Massachusetts General Hospital.
Immunohistochemistry
Rodent brains were removed, frozen in OCT and 7 lm sections were obtained by cryostat. Tissue slides were dried and fixed in ice-cold acetone at -20°C for immunohistochemistry and standard hematoxylin and eosin (H and E) staining. After blocking with serum, sections were incubated with rat anti-CD34 (MEC14.7, Abcam) or mouse anti-Ki67 (MIB-1, Dako) antibodies overnight at 4°C. Immpress anti-rat Ig or Vectastain Elite kit (both from Vector) were used for CD34 and Ki67 staining, respectively, and color was developed with DAB (Dako). Sections were counterstained with hematoxylin, dehydrated, and mounted. Three slides (anterior, mid, and posterior regions of tumor) from each brain (n = 3/group) were selected and three microscopic tumor areas per slide were subjected to the measurement of CD34-immunopositive areas using NIH Image-J software. To quantify MIB-1 positivity, at least 500 cells were counted from randomly chosen fields per tumor (n = 3/group).
Statistical analysis
Tube formation assays were analyzed using one-way ANOVA followed by Tukey's multiple comparison test. Microvascular densities and Ki67 labeling indices were compared using the unpaired student t test (two-tailed). Sphere forming efficiency was analyzed with Fisher's exact test (two-tailed). Survival was analyzed by Kaplan-Meier curves, and comparisons were determined by Log-rank (Mantel-Cox) test and Gehan-Breslow-Wilcoxon test. All statistical analysis was conducted using Prism, and p values less than 0.05 were considered significant.
Results
Axitinib cytotoxicity of GBM cells, GSCs and endothelial cells in vitro
We first determined the sensitivity of GBM cells to axitinib (Fig. 1a) . Three of four human GSC lines tested were sensitive to axitinib; IC50s for MGG4 and MGG18 were 2.1 and 6.4 lM, respectively, while MGG8, which has PDGFRA amplification, was highly sensitive with an IC50 of only 0.06 lM (Fig. 1a) . BT74 GSCs were resistant to axitinib up to 300 lM. Established U87 glioma cell line was also mostly resistant to axitinib, with about a 25 % reduction in cell viability at 10 lM. As expected, HUVECs were very sensitive to axitinib with its IC50 about 0.3 lM (Fig. 1a) . Furthermore, in vitro tube formation by HUVEC and HBMEC was inhibited by 65-70 % at 0.03 lM of axitinib (Fig. 1b, c , p \ 0.0001).
Axitinib inhibits sphere formation by GSCs and induces their apoptosis
We next wanted to determine whether axitinib treatment affects the stem-like properties of GSCs. As a surrogate of self-renewal, clonogenicity was assessed. Axitinib at the IC20 doses impaired secondary sphere formation by MGG4 and MGG8 seeded at clonogenic densities (Fig. 2a,  b) , indicating an inhibition of GSC self-renewal. At higher concentrations, axitinib induced apoptosis in MGG4 as shown by increases in fractions of cells positive for Annexin V and propidium iodide after 48-hour drug exposure (Fig. 2c) . Anti-tumor and anti-angiogenic effects of axitinib in intracranial U87 glioma
The anti-tumor activity of axitinib for malignancies located in the CNS has not been investigated. We therefore tested whether daily systemic administration of axitinib was efficacious for established U87 intracranial tumors in mice. Since U87 is resistant to axitinib (Fig. 1a) , the anti-tumor effects of axitinib in vivo are attributable to its impact on the tumor microenvironment. The median survival for the axitinib group was 34.5 days compared to 30 days for the control group (Fig. 3a , p = 0.002 with log-rank test, p = 0.004 with Gehan-Breslow-Wilcoxon test). Histopathology of tumor sections revealed that the axitinib-treated tumors had a 25 % decrease in tumor cellularity compared with the vehicletreated tumors (Fig. 3b, p = 0.002 ). In line with this, axitinib significantly lowered the Ki67 labeling index of the treated tumors, revealing the ability of axitinib to suppress proliferation of neoplastic cells in the brain (Fig. 3c, p = 0.0003) .
To analyze the effects of axitinib on tumor-associated vasculature, we performed immunohistochemisty for CD34, a commonly used endothelial marker. In vehicletreated tumors, there was striking hypervascularity characterized by irregular-shaped and often tortuous or dilated blood vessels, a hallmark of GBM-associated aberrant angiogenesis (Fig. 3d) . In contrast, axitinibtreated U87 tumors showed nearly complete disappearance of such features and displayed generally thin-walled, undilated vasculature that resembles the vasculature seen in the normal brain (Fig. 3d) . Quantitative analysis of CD34 microvascular densities confirmed the antiangiogenic effects as axitinib greatly decreased ([90 %, p = 0.0002) the microvascular density compared to vehicle treatment (Fig. 3d) . Thus systemic axitinib treatment had anti-proliferative and potent anti-angiogenic effects in the orthotopic hypervascular U87 glioma model, which was associated with extended survival of the animals. 
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Since the U87 glioma cell line model does not recapitulate the molecular pathology found in human GBM, we next used a more representative model generated from GSCs isolated from primary GBM specimens. We chose MGG4 because this GSC line generates hypervascular and hypoxic tumors [28, 30, 35] , and thus provides a useful model to investigate anti-angiogenic strategies [36] . Athymic mice bearing intracranial MGG4 tumors were treated with either axitinib or vehicle solution, and animals followed for survival. Kaplan-Meier survival analysis showed that axitinib significantly extended survival (median survival: 80 days) compared to the control group (median survival: 75 days, p = 0.04 with log-rank test, p = 0.04 with Gehan-Breslow-Wilcoxon test) (Fig. 4a) . Histopathologically, vehicle-treated MGG4 tumors exhibited frequent dilated and tortuous vasculature that was immunopositive for CD34, while axitinib-treated tumors had reduced vascular abnormalities (Fig. 4b) . There was no difference in the weights of the vehicle-and axitinib-treated mice, indicating that axitinib at the administered dose was not toxic (Supplementary Fig. S1 ).
Axitinib efficacy in a mouse GSC-derived orthotopic GBM model Finally, given reported roles for VEGFR signaling in regulating innate immune cell recruitment [37] and adaptive cellular immunity [38] [39] [40] , we sought to determine axitinib efficacy in a GBM model with an intact immune system. To this end, we employed the mouse 005 GSC model that exhibits the pathological hallmarks of GBM, hypervascularity and invasiveness [34] . In this aggressive orthotopic GBM model, treatment with axitinib modestly but significantly prolonged the survival of tumor-bearing mice (Fig. 5a , median survival: 43 versus 38.5 days, p = 0.0001 with log-rank test, p = 0002 with Gehan-Breslow-Wilcoxon test), recapitulating the results we observed in the two human GBM xenografts. CD34 immunohistochemistry showed that axitinib efficacy was associated with decreased vascularity in axitinib-treated tumors compared to the control (Fig. 5b) .
Discussion
In this study, we show for the first time that the VEGFR TKI axitinib exhibits anti-angiogenic activity and prolongs survival of mice bearing orthotopic GBMs. The therapeutic activity of axitinib was demonstrated in three hypervascular intracerebral GBM models: conventional U87 glioma, MGG4 GSCs and mouse 005 GSCs. Our in vitro investigation indicated that axitinib not only suppresses the viability of endothelial cells but also GSCs isolated from three of four patients, with sensitivities ranging from IC50s of 0.06-6 lM. Axitinib was previously shown to inhibit the growth of 9L rat gliosarcoma cells in vitro [41] . Although traditionally VEGFR2 was regarded as an endothelial specific protein, recent research described an autocrine VEGF-VEGFR2-Neuropilin-1 signaling pathway that promotes GSC viability and tumor growth [42] . Thus, the observed cytotoxic effect mediated by axitinib, including sphere forming suppression and apoptosis induction, may be through its inhibition of VEGFRs. Notably, MGG8 GSC was the most sensitive to axitinib, which may have been due to inhibition of PDGFR since MGG8 has PDGFRA gene amplification [30] . In contrast, U87 was relatively resistant to axitinib. It will be of interest to study whether undifferentiated GSCs are more sensitive to the direct impact of axitinib compared to more differentiated GBM cells.
In subcutaneous tumor models, axitinib treatment inhibited growth of rat 9L [41] , and human U87 [18] and U251 gliomas [37] , although tumor growth resumed after cessation of axitinib treatment [37] . In order to evaluate the anti-angiogenic and anti-tumor effects of axitinib on tumors located in the brain, we selected three orthotopic GBM models that are highly vascular. In the commonly used U87 model, daily axitinib treatment prominently reduced tumor-associated microvascular density and prolonged survival. The MGG4 GSC-derived tumor model displays frequent abnormally dilated and tortious blood vessels and intratumoral hemorrhages, a vascular hallmark of human GBM [28, 30, 36] . CD34 endothelium staining revealed axitinib-mediated anti-angiogenic effects in the MGG4 and 005 models as well. While survival was significantly extended in all three orthotopic GBM models by axitinib treatment, the effects were modest. This suggests that despite robust inhibition of angiogenesis in these vascular tumors, tumor growth was not dependent upon neovascularization. In the MGG4 model, where MGG4 GSCs are sensitive to axitinib in vitro, both direct impacts on tumor cells and inhibition on tumor vasculature may contribute to the survival benefit. Cediranib and axitinib share a very similar tyrosine kinase inhibition profile, blocking VEGFR1-3, PDGFRb, and c-Kit [18, 43] . Preclinically, cediranib extended survival of mice bearing intracerebral GBMs, including U87, without altering the growth kinetics of tumors [44] . A randomized phase 3 clinical trial testing cediranib with and without lomustine for recurrent GBM showed that the use of cediranib delayed the time to neurological deterioration and had corticosteroid sparing effect, however it failed to demonstrate an effect on PFS [13] . In a phase 2 trial of cediranib for newly diagnosed GBM patients, cediranib induced an increase of tumor perfusion in a subset of patients and these responders had an overall survival benefit [14] . This improved blood perfusion and alleviated GBM-associated edema indicates some clinical activity of cediranib for at least a subset of GBM patients. In this study, we observed a notable disappearance of dilated CD34 ? vessels in the U87 and MGG4 models, which is consistent with the induction of vascular normalization. Analysis of molecular interactions of several TKIs and VEGFR2 identified a positive correlation between in vitro ligand efficiency (LipE) and PFS in renal cell carcinoma trials [45] . Axitinib is superior to cediranib in LipE, kinase Ki, as well as HU-VEC IC50 for both VEGFR2 phosphorylation and survival [45] , suggesting that axitinib may perform better in the clinic than cediranib, as was the case for axitinib and sorafenib [24] . These targeting properties, ability to penetrate the brain, and possible inhibitory effects on GBM cells could confer axitinib with an advantage over anti-angiogenic antibodies, such as the VEGF antibody bevacizumab, which was recently shown to provide no overall survival benefit for newly diagnosed GBMs [15, 16] .
Although axitinib extended survival, long-term disease control or cures were not obtained in any model tested, despite large decreases in neovascularization. This suggests that clinical use of axitinib as monotherapy for GBM would not be efficacious in prolonging overall survival. Combinatory approaches with other therapeutic modalities may be able to overcome limitations with anti-angiogenic strategies and enhance efficacy. However, selection of combinatorial partners with VEGFR TKI needs caution as subcutaneous glioma tumor regression induced by metronomic cyclophosphamide chemotherapy was inhibited by axitinib due to inhibition of innate anti-tumor immune cell recruitment [37] . We previously showed that bevacizumabmediated reduced vascular permeability enhances distribution of intratumorally injected therapeutic oncolytic herpes simplex virus (oHSV) [46] . When systemic bevacizumab was combined with oHSV expressing antiangiogenic angiostatin (G47D-mAngio), there was marked increase in survival of mice bearing intracerebral U87 GBM [46] . It will be of interest to investigate whether axitinib and oHSV have similar synergistic effects in GSCderived orthotopic GBM models.
In summary, we show for the first time that systemic daily treatment with axitinib markedly inhibited GBMassociated angiogenesis and modestly extended survival in three preclinical orthotopic GBM models. These results support further investigation of axitinib as an anti-angiogenic agent for GBM.
